2R3T

I50V HIV-1 protease mutant in complex with a carbamoyl decorated pyrrolidine-based inhibitor

Summary for 2R3T

• Entry DOI: 10.2210/pdb2r3t/pdb
• Related: 2R38 2R3W 2R43
• Descriptor: Protease, CHLORIDE ION, 4,4'-{(3S,4S)-PYRROLIDINE-3,4-DIYLBIS[(BENZYLIMINO)SULFONYL]}DIBENZAMIDE, ... (4 entities in total)
• Functional Keywords: protein-ligand complex, aspartyl protease, hydrolase, protease
• Biological source: Human immunodeficiency virus 1
• Total number of polymer chains: 2
• Total formula weight: 22262.67

Authors

Boettcher, J.,Blum, A.,Heine, A.,Diederich, W.E.,Klebe, G. (deposition date: 2007-08-30, release date: 2008-09-02, Last modification date: 2023-08-30)

Primary citation

Bottcher, J.,Blum, A.,Heine, A.,Diederich, W.E.,Klebe, G.
Structural and Kinetic Analysis of Pyrrolidine-Based Inhibitors of the Drug-Resistant Ile84Val Mutant of HIV-1 Protease
J.Mol.Biol., 383:347-357, 2008

PubMed Abstract: Human immunodeficiency virus (HIV) protease is a well-established drug target in HIV chemotherapy. However, continuously increasing resistance towards approved drugs inevitably requires the development of new inhibitors preferably showing no susceptibility against resistant HIV protease strains. Recently, symmetric pyrrolidine-3,4-bis-N-benzyl-sulfonamides have been developed as a new class of HIV-1 protease inhibitors. The most promising candidate exhibited a K(i) of 74 nM towards a wild-type protease. Herein, we report the influence of the active-site mutations Ile50Val and Ile84Val on these inhibitors by structural and kinetic analysis. Although the Ile50Val mutation leads to a significant decrease in affinity for all compounds in this series, they retain or even show increased affinity towards the important Ile84Val mutation. By detailed analysis of the crystal structures of two representatives in complex with wild-type and mutant proteases, we were able to elucidate the structural basis of this phenomenon.

PubMed: 18692068
DOI: 10.1016/j.jmb.2008.07.062

Experimental method

X-RAY DIFFRACTION (1.8 Å)